An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report

被引:1
|
作者
Wang, Chen-Ti [1 ]
Chang, Che-Wei [1 ]
Lu, Yung-Chuan [1 ]
Lam, Hing-Chung [1 ]
Ku, Shu-Ju [1 ]
Tseng, Kuo-Bin [2 ]
Kao, Yu-Hsi [1 ]
机构
[1] I Shou Univ, E Da Hosp, Dept Internal Med, Div Endocrinol & Metab, 1 Yida Rd, Kaohsiung 824, Taiwan
[2] I Shou Univ, E Da Canc Hosp, Dept Internal Med, Div Endocrinol & Metab, 21 Yida Rd, Kaohsiung 824, Taiwan
关键词
Atypical hyperosmolar hyperglycemic state; Diabetic ketoacidosis; Geriatrics; Sodium-glucose cotransporter-2 inhibitors; Type; 2; diabetes; MELLITUS; SGLT2; DAPAGLIFLOZIN; MORTALITY; SAFETY; CRISES;
D O I
10.1016/j.jfma.2019.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have become the best choice of second -line oral antidiabetic drugs for patients with heart or chronic kidney disease. However, it is not clear how safe this treatment is for elderly patients, especially Asians, who are known to be more insulin deficient than Caucasian individuals with a similar insulin resistance. Here, we report a case concerning an elderly patient with type 2 diabetes mellitus without insulin dependence, whose antidiabetic medication had recently been changed to include an SGLT-2 inhibitor. The patient presented with an atypical hyperosmolar hyperglycemic state and dia-betic ketoacidosis but recovered after insulin pump treatment and fluid supplementation. The patient was discharged with a prescription of a mixed-type insulin injection instead of oral antidiabetic medications for diabetes control. Our case demonstrates that if SGLT-2 inhibitors are administered to elderly Asian patients, their benefits and adverse effects should be care-fully monitored. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码:1325 / 1328
页数:4
相关论文
共 50 条
  • [21] Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
    Afzal, Muhammad
    Al-Abbasi, Fahad A.
    Nadeem, Muhammad Shahid
    Alshehri, Sultan
    Ghoneim, Mohammed M.
    Imam, Syed Sarim
    Almalki, Waleed Hassan
    Kazmi, Imran
    METABOLITES, 2021, 11 (11)
  • [22] Sodium glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
    Bitar, Zouheir Ibrahim
    Maadarani, Ossama Sajeh
    Alabdali, Fawaz
    Teama, Ahmed
    Elsawah, Walid
    Mohsen, Mohammed Jaber
    Elzoueiry, Mahmoud Mostafa
    CLINICAL CASE REPORTS, 2022, 10 (02):
  • [23] Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature
    Chacko, B.
    Whitley, M.
    Beckmann, U.
    Murray, K.
    Rowley, M.
    ANAESTHESIA AND INTENSIVE CARE, 2018, 46 (02) : 215 - 219
  • [24] Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors
    Auerbach, Jonathan S.
    Gershengorn, Hayley B.
    Aljure, Oscar D.
    Lamelas, Joseph
    Patel, Samira S.
    Ferreira, Tanira D.
    Gonzalez, Lazaro A.
    Cabrera, Jorge L.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2023, 37 (06) : 956 - 963
  • [25] Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor
    Koch, Richard A.
    Clark, Richard F.
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (05) : E590 - E591
  • [26] Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor
    Zhang, Lydia
    Tamilia, Michael
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (25) : E766 - E768
  • [27] Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
    Chilton, Robert J.
    DIABETES OBESITY & METABOLISM, 2020, 22 (01) : 16 - 29
  • [28] Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
    Kang, Dong Yoon
    Kim, Hyunah
    Ko, SooJeong
    Kim, HyungMin
    Shinn, Jiwon
    Kang, Min-Gyu
    Byeon, Sun-Ju
    Choi, Jeong-Hee
    Shin, Soo-Yong
    Kim, Hun-Sung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (07)
  • [29] Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
    Profili, Nicia I.
    Castelli, Roberto
    Gidaro, Antonio
    Manetti, Roberto
    Maioli, Margherita
    Delitala, Alessandro P.
    PHARMACEUTICALS, 2024, 17 (11)
  • [30] New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature
    Kietaibl, Antonia-Therese
    Fasching, Peter
    Glaser, Karl
    Petter-Puchner, Alexander H.
    FRONTIERS IN SURGERY, 2022, 9